Biomarker NTRK Coverage from Every Angle
Editors:
Alexander Drilon, MD
Gregory J. Riely, MD, PhD
Advertisement
Advertisement

Available Clinical Trials

A Phase I/II Study of Repotrectinib in Children and Young Adults With Advanced or Metastatic Cancers Containing ALK, ROS1, or NTRK1–3 Alterations
A Phase I/II, Open-Label, Multicenter, First-in-Human Study of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1–3 Rearrangements (TRIDENT-1)
A Study of Alectinib, Entrectinib, Vemurafenib Plus Cobimetinib, or Pralsetinib in Patients With Resectable Stages II-III Non-Small Cell Lung Cancer With ALK, ROS1, NTRK, BRAF V600, or RET Molecular Alterations
A Study to Evaluate Larotrectinib to Treat Patients With Previously Untreated TRK Fusion Solid Tumors and TRK Fusion Relapsed Acute Leukemia
A Study to Test the Safety and Efficacy of Larotrectinib in Treatment of Tumors With <em>NTRK</em> Fusion in Children (SCOUT)
CONNECT 1903: Larotrectinib for Children With Newly Diagnosed High-Grade Glioma With NTRK Fusion
Genetic Testing in Guiding Treatment of Patients With Brain Metastases
Larotrectinib for the Treatment of <em>NTRK</em> Amplification–Positive, Locally Advanced or Metastatic Solid Tumors
Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)
Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions
Multicenter, Phase II, Neoadjuvant and Adjuvant Study of Alectinib, Entrectinib, or Vemurafenib Plus Cobimetinib in Patients with Stages I–III NSCLC With ALK, ROS1, NTRK, or BRAF V600E Molecular Alterations
Real World European Registry of NTRK Fusions and Other Rare Actionable Fusions
Registry for Molecular Testing, Treatment, and Outcome of Patients With Solid Tumors Harboring a NTRK Gene Fusion (REALTRK)
Study to Learn More About the Safety and Effectiveness of the Drug VITRAKVI During Routine Use in Patients With TRK Fusion Cancer Which is Locally Advanced or Spread From the Place Where it Started to Other Places in the Body (ON-TRK)
Copyright © 2023 National Comprehensive Cancer Network, All Rights Reserved
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.